Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Combination creates an integrated provider of drug development and regulatory consulting services serving a complementary client base
The drug discovery of mRNA-targeted small molecules is rapidly gaining attention due to the current difficulty of developing drugs against conventional protein targets
Collaboration supports multiple discovery efforts, including vaccines
The plan is to advance innovative therapies to drug-resistant cancers
AROC3-1001 is a phase 1/2, placebo controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-C3
Effectiveness of Covaxin against the Omicron variant is currently being studied
Whole-genome sequencing to identify genetic mutation; epidemiological studies to help assess the distribution and mathematical modelling to forecast spread
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
